NEW YORK (GenomeWeb) – NeoGenomics today reported a 9 percent year-over-year rise in revenues for the second quarter, driven by growth in clinical testing and pharma services. The firm's revenue growth for the quarter was 12 percent after adjusting 2017 results for the divestiture of PathLogic last August.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.